Triage for the early detection of cervical cancer in HR-HPV+ women, based on an epigenetic signature consisting of 6 markers. With a >99.9% sensitivity, cervical cancer can be ruled out. It also provides molecular information on the risk of malignancy in precancerous lesions based on the methylation pattern status.
The test results complement other clinical findings, such as colposcopies and biopsies, facilitating therapeutic decisions and early diagnosis.
Turnaround time: 5 working days from receipt of the sample
Reference: GYN1001
Please remember to attach the Informed Consent Form to the sample, which you will find on the right.
